Cardiff Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This is a Current Report on Form 8-K filed by Cardiff Oncology, Inc. (CRDF) on January 31, 2022. The company is incorporated in Delaware and trades on the Nasdaq Capital Market. The report covers events occurring on January 31, 2022.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
On January 31, 2022, the company granted non-qualified stock option awards to one new employee. The awards allow for the purchase of an aggregate of 55,008 shares of the company's common stock.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific stock option grant event.
Investor Verification Checklist
- Verify the terms and vesting schedule of the 55,008 stock options granted to the new employee.
- Review the press release furnished as Exhibit 99.1 for additional context on the hiring.
- Check subsequent filings for any dilution impact on existing shareholders.